ReviewInterventional radiology (Higashimatsuyama-shi (Japan)2025
The New Updated Barcelona Clinic Liver Cancer Staging System: Roles of Trans-arterial Chemoembolization and Homework to Interventional Radiologists.
Review in Interventional radiology (Higashimatsuyama-shi (Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Efficacy and safety of conventional transarterial chemoembolization for hepatocellular carcinoma using a glass membrane emulsification device: comparison with a three-way stopcock.Japanese journal of radiology · 2026Article
- Selective Conventional Transarterial Chemoembolization Using a Glass Membrane Emulsification Device in Hepatocellular Carcinoma: Multicenter Clinical Trial in Japan.Liver cancer · 2026Article
- Conversion Liver Resection for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus after Single Tremelimumab Regular Interval Durvalumab Regimen as a Second-Line Therapy: A Case Report.Surgical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Barcelona Clinic Liver Cancer staging system, which has been identified as the most commonly used staging system in patients with hepatocellular carcinoma, was initially published in 1999, and it was updated in 2022. This new Barcelona Clinic Liver Cancer staging shows more flexible strategies for the treatment of hepatocellular carcinoma based on each stage. Although the roles of trans-arterial chemoembolization were limited in intermediate stage (Barcelona Clinic Liver Cancer-B) patients in the previous version, its roles have been expanded in the new version of Barcelona Clinic Liver Cancer staging system. In this manuscript, we introduce how trans-arterial chemoembolization is incorporated in a new Barcelona Clinic Liver Cancer staging system and explore the new role of trans-arterial chemoembolization and what interventional radiologists seek for in a near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.